2 completed, 1 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
Follow NonHodgkin Lymphoma: new trials by email Literature Review of NonHodgkin Lymphoma trials Research Report on NonHodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma TAS4464 - Multiple Myeloma, NonHodgkin Lymphoma | Phase 1 | Terminated | Taiho Oncology, Inc. | 11 | 2017-03-01 | 2024-09-05 |
| A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) Evorpacept (ALX148), Pembrolizumab, Trastuzumab - Metastatic Cancer, Solid Tumor | Phase 1 | Completed | ALX Oncology Inc. | 174 | 2017-02-03 | 2025-08-01 |
| Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) EBVST Cells, Nivolumab - NonHodgkin Lymphoma, Lymphoproliferative Disorders | Phase 1 | Completed | Baylor College of Medicine | 8 | 2016-02-16 | 2021-07-21 |
Lymphoma, Non-Hodgkin (3) · Neoplasms (2) · Hematologic Diseases (1) · Hodgkin Disease (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell, Peripheral (1) · Lymphoproliferative Disorders (1) · Multiple Myeloma (1) · Neoplasm Metastasis (1) · Neoplasms, Plasma Cell (1) · Recurrence (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Neoplasms by Histologic Type (3) · Lymphoma (2) · Lymphoproliferative Disorders (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Disease Attributes (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Lymphoma, B-Cell (1)
ALX148 (1) · Cisplatin (1) · Fluorouracil (1) · Nivolumab (1) · Paclitaxel (1) · Ramucirumab (1) · Rituximab (1) · TAS4464 (1) · Trastuzumab (1) · pembrolizumab (1)
ALX Oncology Inc. (1) · Baylor College of Medicine (1) · Taiho Oncology, Inc. (1)
United States (3) · South Korea (1)
Ravi Pingali, MD (1)